Clinical trials: Human
Influenza
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
The purpose of this study is to evaluate the immunogenicity and safety of the new influenza vaccine GSK2282512A (FLU Q-QIV) and compare its activity to Sanofi Pasteur's Fluzone® (TIV) in children 6 to 35 months of age.
- Trial name
- NCT01974895
- Testing
- FluLaval® Quadrivalent, Fluzone®
- Where
- 12 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Plasma Cell Neoplasm
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00547365
- Testing
- Human immune globulin intravenous (IGIV)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Tennessee
Growth Hormone Deficiency (GHD)
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis.
- Trial name
- NCT01947907
- Testing
- ACP-001, Human Growth Hormone
- Where
- 36 sites in Belarus, Bulgaria and 12 more
- Volunteers
- 53 people
- Sponsor
- Ascendis Pharma A/S
Influenza
Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Background: Influenza (flu) is a virus that infects people of all ages. Some people may have mild flu symptoms. Others may get very sick and even die from the flu.
- Trial name
- NCT05027932
- Testing
- BPL-1357
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Cancer, Oropharyngeal Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Background: The human papillomavirus (HPV) can cause a number of cancers, including cervical and throat cancers. The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white…
- Conditions
- Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer
- Trial name
- NCT01585428
- Testing
- Fludarabine, Cyclophosphamide, Young TIL
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C, Chronic
Directly Observed Therapy for HCV in Chennai, India
The primary objective of this pilot trial is to evaluate the feasibility of 12 weeks vs. 24 weeks of field-based directly observed therapy (DOT) for HCV therapy in a resource-limited setting.
- Trial name
- C-DOT (NCT02541409)
- Testing
- Sofosbuvir, Pegylated Interferon alfa-2a, Ribavirin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Hepatitis, HIV/AIDS
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
Background: Standard treatment for the hepatitis C virus (HCV) is a combination of the drugs peg-IFN and ribavirin. However, this treatment is not very effective in people with a serious type of HCV (HCV genotype 1) and also in…
- Trial name
- NCT01443923
- Testing
- Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Restrictive Scar Contracture, Restrictive Hypertrophic Scar
A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures
The primary objective of this study is to evaluate the safety of ICX-RHY-013 in the treatment of stable, restrictive scars in subjects who have suffered a burn injury.
- Conditions
- Restrictive Scar Contracture, Restrictive Hypertrophic Scar, Burn Scar Contractures, Burn Scar
- Trial name
- NCT01564407
- Testing
- ICX-RHY-013
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Chronic Hepatitis B
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus…
- Trial name
- NCT04398134
- Testing
- ABI-H2158, Entecavir (ETV)
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 88 people
- Sponsor
- Assembly Biosciences
Influenza
Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)
The investigators collected blood and lymphoid tissues routinely discarded during surgery from adults after a routine seasonal influenza vaccination to determine how immune memory develops at the actual site of infection, and how…
- Trial name
- NCT03023709
- Testing
- Fluzone®, FluMist®
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Depression, Melancholia
Antidepressant Treatment of Melancholia in Late Life
The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have…
- Trial name
- NCT00000378
- Testing
- Sertraline, Nortriptyline
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- New York State Psychiatric Institute
Chronic Hepatitis B
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
The purpose of this study is to evaluate the efficacy and safety following the Roadmap Concept strategy with an initial monotherapy using either telbivudine or tenofovir in HBeAg negative CHB patients.
- Trial name
- NCT01379508
- Testing
- telbivudine, tenofovir disoproxil fumarate
- Where
- 34 sites in Austria, Bulgaria and 6 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
- Trial name
- REACH (NCT01140347)
- Testing
- Ramucirumab DP (IMC-1121B), BSC
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 565 people
- Sponsor
- Eli Lilly and Company
Hepatitis B, Chronic
Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
The presence of persistent inadequate or suboptimal virologic response is a strong risk factor for viral resistance and breakthrough and also for disease progression of chronic hepatitis B, and thus, a change in therapy is…
- Trial name
- CAESAR (NCT01023217)
- Testing
- Adefovir, Entecavir, Lamivudine
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Asan Medical Center
Chronic Hepatitis c, Cirrhosis, Liver
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to…
- Conditions
- Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
- Trial name
- HALT-C (NCT00006164)
- Testing
- Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
- Where
- 11 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Influenza, Human, Influenza in Birds
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
This is a Phase 2, randomized, multi-center study in approximately 300 adults who received 2 doses of aH5N1c or placebo in and completed the parent study V89_18 in the <65 years of age cohort.
- Conditions
- Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections
- Trial name
- NCT05422326
- Testing
- aH5N6c on Day 1, aH5N6c on Day 22
- Where
- 18 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Seqirus
Castleman Disease, Multicentric Castleman Disease
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Background: Kaposi's sarcoma-associated herpes virus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is caused by a herpes virus known as KSHV.
- Conditions
- Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
- Trial name
- NCT01441063
- Testing
- Zidovudine, Tocilizumab, Valganciclovir (VGC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloproliferative Disorders
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
The study is designed as a Phase III, randomized, open label, multicenter, prospective, comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) versus marrow from unrelated…
- Conditions
- Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
- Trial name
- NCT00075816
- Testing
- Allogeneic bone marrow transplantation, Peripheral blood stem cell transplantation
- Where
- 45 sites in United States, Canada
- Volunteers
- 551 people
- Sponsor
- Medical College of Wisconsin
Indication for Peripheral Intravenous Catheterisation
Impact of PIVC Length and Gauge on Catheter Indwell Time
This is a single-centre, open-label, multi-visit study design, in 40 healthy participants, randomized by gauge of peripheral intravenous catheter (PIVC) device into the lower arm cephalic vein of both arms.
- Trial name
- NCT04344314
- Testing
- Peripheral Intravenous Catheter
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Becton, Dickinson and Company
Prostate Cancer
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of BNT112 cancer vaccine (BNT112) monotherapy or in combination with cemiplimab…
- Trial name
- PRO-MERIT (NCT04382898)
- Testing
- BNT112, Cemiplimab
- Where
- 22 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.